Cahn, A <br/><br/>
Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.  [electronic resource] 

 -  Pulmonary pharmacology & therapeutics  Oct 2017 
 - 69-77 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1522-9629 
<br/><br/><label>Standard No.: </label>10.1016/j.pupt.2017.08.008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Inhalation<br/>Aged<br/>Class I Phosphatidylinositol 3-Kinases--antagonists & inhibitors<br/>Cytokines--metabolism<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Forced Expiratory Volume<br/>Humans<br/>Indazoles--administration & dosage<br/>Indoles<br/>Male<br/>Middle Aged<br/>Oxazoles--administration & dosage<br/>Piperazines<br/>Pulmonary Disease, Chronic Obstructive--drug therapy<br/>Severity of Illness Index<br/>Sputum--metabolism<br/>Treatment Outcome